Inhibitor Therapeutics, Inc.
US ˙ OTCPK

Introduction

This page provides a comprehensive analysis of the known insider trading history of Watson W. Mark. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Watson W. Mark has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:VXRT / Vaxart, Inc. Director 104,125
US:BDSI / Biodelivery Sciences International Director 0
Director 0
US:INTI / Inhibitor Therapeutics, Inc. Director 1,306,452
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Watson W. Mark. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases INTI / Inhibitor Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in INTI / Inhibitor Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2019-12-12 INTI Watson W. Mark 500 0.0619 500 0.0619 31 180 0.1035 22 72.50
2014-09-08 HPPI Watson W. Mark 10,000 0.1300 10,000 0.1300 1,300

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

INTI / Inhibitor Therapeutics, Inc. Insider Trades
Insider Sales INTI / Inhibitor Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in INTI / Inhibitor Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

INTI / Inhibitor Therapeutics, Inc. Insider Trades
Insider Purchases VXRT / Vaxart, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in INTI / Inhibitor Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2025-07-29 VXRT Watson W. Mark 10,000 0.4050 10,000 0.4050 4,050 730
2024-06-18 VXRT Watson W. Mark 20,000 0.6789 20,000 0.6789 13,578
2022-12-28 VXRT Watson W. Mark 20,000 0.7570 20,000 0.7570 15,140

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VXRT / Vaxart, Inc. Insider Trades
Insider Sales VXRT / Vaxart, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in INTI / Inhibitor Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VXRT / Vaxart, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Watson W. Mark as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-07-31 2025-07-29 4 VXRT Vaxart, Inc.
Common Stock
P - Purchase 10,000 104,125 10.62 0.40 4,050 42,171
2025-06-16 2025-06-13 4 VXRT Vaxart, Inc.
Common Stock
A - Award 16,000 94,125 20.48
2024-06-20 2024-06-18 4 VXRT Vaxart, Inc.
Common Stock
P - Purchase 20,000 78,125 34.41 0.68 13,578 53,039
2024-06-12 2024-06-11 4 VXRT Vaxart, Inc.
Common Stock
A - Award 16,000 58,125 37.98
2023-08-01 2023-06-26 4 VXRT Vaxart, Inc.
Common Stock
A - Award 7,375 42,125 21.22
2022-12-28 2022-12-28 4 VXRT Vaxart, Inc.
Common Stock
P - Purchase 20,000 20,000 0.76 15,140 15,140
2022-08-08 2022-08-04 4 VXRT Vaxart, Inc.
Common Stock
A - Award 14,750 14,750
2022-03-22 2022-03-22 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Stock Options (right to buy)
D - Sale to Issuer -85,760 0 -100.00
2022-03-22 2022-03-22 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Stock Options (right to buy)
D - Sale to Issuer -54,740 0 -100.00
2022-03-22 2022-03-22 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units
D - Sale to Issuer -22,685 0 -100.00
2022-03-22 2022-03-22 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock
J - Other -90,663 0 -100.00
2022-01-31 2022-01-27 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units
M - Exercise -7,684 7,685 -50.00
2022-01-31 2022-01-27 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units
A - Award 15,369 15,369
2022-01-31 2022-01-27 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Stock Options (right to buy)
A - Award 85,760 85,760 3.66 313,882 313,882
2022-01-31 2022-01-27 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock
M - Exercise 7,684 90,663 9.26
2021-08-27 2021-08-27 4 SYKE SYKES ENTERPRISES INC
Common Stock
D - Sale to Issuer -13,491 0 -100.00
2021-08-10 2021-08-06 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units
M - Exercise -30,000 15,000 -66.67
2021-08-10 2021-08-06 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock
M - Exercise 30,000 82,979 56.63
2021-05-19 2021-05-19 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 694 11,409 6.48 41.43 28,752 472,675
2021-02-22 2021-02-22 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 181 10,715 1.72 41.93 7,589 449,280
2021-02-16 2021-02-16 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 1,000 10,534 10.49 42.86 42,860 451,487
2020-12-28 2020-12-22 4 INTI Inhibitor Therapeutics, Inc.
Common Stock Option
A - Award 1,306,452 1,306,452
2020-11-23 2020-11-23 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 181 9,534 1.94 37.90 6,860 361,339
2020-11-13 2020-11-13 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 1,000 9,353 11.97 37.20 37,200 347,932
2020-08-24 2020-08-24 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 181 8,353 2.21 33.42 6,049 279,157
2020-08-19 2020-08-17 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock
S - Sale -13,000 52,979 -19.70 5.18 -67,340 274,431
2020-08-13 2020-08-13 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 1,000 8,172 13.94 34.36 34,360 280,790
2020-08-11 2020-08-07 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units
M - Exercise -30,000 45,000 -40.00
2020-08-11 2020-08-07 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock
M - Exercise 30,000 65,979 83.38
2020-05-22 2020-05-22 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 181 7,172 2.59 25.95 4,697 186,113
2020-05-13 2020-05-13 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 1,000 6,991 16.69 25.00 25,000 174,775
2020-03-30 2020-03-30 4 SYKE SYKES ENTERPRISES INC
Common Stock
S - Sale -3,000 5,991 -33.37 26.10 -78,300 156,365
2020-03-24 2020-03-20 4 INTI Inhibitor Therapeutics, Inc.
Common Stock Option
A - Award 1,500,000 1,500,000
2020-02-24 2020-02-24 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 181 8,991 2.05 35.67 6,456 320,709
2020-02-21 2020-02-21 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 983 8,810 12.56 35.95 35,339 316,720
2020-02-10 2019-12-12 5 INTI Inhibitor Therapeutics, Inc.
Common Stock
P - Purchase 500 1,054,100 0.05 0.06 31 65,249
2019-11-22 2019-11-22 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 181 7,827 2.37 34.92 6,321 273,319
2019-11-21 2019-11-21 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 984 7,646 14.77 35.27 34,706 269,674
2019-08-22 2019-08-22 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 181 6,662 2.79 29.19 5,283 194,464
2019-08-21 2019-08-21 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 984 6,481 17.90 28.89 28,428 187,236
2019-08-15 2019-08-13 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units
M - Exercise -24,739 74,640 -24.89
2019-08-15 2019-08-13 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock
M - Exercise 24,739 35,979 220.10
2019-06-10 2019-06-03 4 HPPI HedgePath Pharmaceuticals, Inc.
Common Stock Option
A - Award 25,000 25,000
2019-05-22 2019-05-22 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 180 5,497 3.39 25.75 4,635 141,548
2019-05-21 2019-05-21 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 984 5,317 22.71 25.41 25,003 135,105
2019-02-25 2019-02-25 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 904 4,333 26.36 31.10 28,114 134,756
2019-02-22 2019-02-22 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 180 3,429 5.54 30.51 5,492 104,619
2019-02-05 2019-02-03 4 HPPI HedgePath Pharmaceuticals, Inc.
Common Stock Option
A - Award 657,895 657,895
2018-11-26 2018-11-22 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 180 2,346 8.31 26.82 4,828 62,920
2018-11-26 2018-11-23 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 903 3,249 38.49 26.82 24,218 87,138
2018-08-23 2018-08-23 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 903 2,166 71.50 29.31 26,467 63,485
2018-08-22 2018-08-22 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 180 1,263 16.62 29.42 5,296 37,157
2018-08-16 2018-08-14 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units
M - Exercise -9,740 99,379 -8.93
2018-08-16 2018-08-14 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock
M - Exercise 9,740 11,240 649.33
2018-08-03 2018-08-01 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Stock Options (right to buy)
A - Award 54,770 54,770
2018-08-03 2018-08-01 4 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units
A - Award 109,479 109,479
2018-05-30 2018-05-23 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 903 1,083 501.67 27.68 24,995 29,977
2018-05-25 2018-05-22 4 SYKE SYKES ENTERPRISES INC
Common Stock
A - Award 180 180 27.69 4,984 4,984
2018-03-15 2018-03-13 4 HPPI HedgePath Pharmaceuticals, Inc.
Common Stock Option
A - Award 76,000 76,000
2018-03-15 2018-03-13 4 HPPI HedgePath Pharmaceuticals, Inc.
Common Stock Option
A - Award 253,000 253,000
2017-12-08 3 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock
3,000
2017-12-08 3 BDSI BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock
3,000
2017-03-10 2017-03-08 4 HPPI HedgePath Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -200,000 0 -100.00
2017-03-10 2017-03-08 4 HPPI HedgePath Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -400,000 0 -100.00
2017-03-10 2017-03-08 4 HPPI HedgePath Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -300,000 0 -100.00
2017-03-10 2017-03-08 4 HPPI HedgePath Pharmaceuticals, Inc.
Common Stock
F - Taxes -79,200 553,600 -12.52 0.34 -26,928 188,224
2017-03-10 2017-03-08 4 HPPI HedgePath Pharmaceuticals, Inc.
Common Stock
M - Exercise 200,000 632,800 46.21
2017-03-10 2017-03-08 4 HPPI HedgePath Pharmaceuticals, Inc.
Common Stock
F - Taxes -158,400 432,800 -26.79 0.34 -53,856 147,152
2017-03-10 2017-03-08 4 HPPI HedgePath Pharmaceuticals, Inc.
Common Stock
M - Exercise 400,000 591,200 209.21
2017-03-10 2017-03-08 4 HPPI HedgePath Pharmaceuticals, Inc.
Common Stock
F - Taxes -118,800 191,200 -38.32 0.34 -40,392 65,008
2017-03-10 2017-03-08 4 HPPI HedgePath Pharmaceuticals, Inc.
Common Stock
M - Exercise 300,000 310,000 3,000.00
2016-07-06 2016-07-01 4 HPPI HedgePath Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 200,000 200,000
2016-07-06 2016-07-01 4 HPPI HedgePath Pharmaceuticals, Inc.
Options to Purchase Common Stock
A - Award 200,000 200,000
2015-08-18 2015-08-14 4 HPPI HedgePath Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 400,000 400,000
2015-02-06 2014-07-18 5 HPPI HedgePath Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 300,000 300,000
2014-09-09 2014-09-08 4 HPPI HedgePath Pharmaceuticals, Inc.
Common Stock
P - Purchase 10,000 10,000 0.13 1,300 1,300
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)